OMER Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Omeros Corp (OMER) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The recent FDA approval of Yartemlea and the subsequent increase in the price target by analysts to $40 indicate strong growth potential. Hedge funds are significantly increasing their positions, and technical indicators show bullish trends. While financials show losses, the approval of Yartemlea is a critical inflection point that could drive future revenue growth.
The MACD is positive and contracting, RSI is neutral at 47.536, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 11.726, with support at 11.191 and resistance at 12.261. These indicators suggest a bullish trend.
FDA approval of Yartemlea for a niche medical condition, which is expected to drive significant revenue.
Hedge funds are heavily buying the stock, indicating institutional confidence.
Analysts have raised the price target to $40, citing the approval as a critical inflection point.
The company is currently unprofitable, with net income and EPS declining YoY.
No recent news or congress trading data to provide additional sentiment validation.
In Q3 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$30.92M, down -4.08% YoY. EPS also dropped to -0.47, down -16.07% YoY. While financials are weak, the recent FDA approval is expected to drive future revenue.
Analysts at H.C. Wainwright have reiterated a Buy rating and raised the price target from $20 to $40, citing the FDA approval of Yartemlea as a significant validation of Omeros' value and a critical inflection point for the company.
